| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CDMO收入(元) | 5,120,501.42 | 52,493,429.77 | 17,275,723.70 | 20,802,162.21 | 7,343,132.65 |
| 临床前药学研究(元) | 154,323,246.34 | 338,110,096.63 | 124,660,591.05 | 218,402,681.62 | 90,344,550.97 |
| 权益分成(元) | 4,554,144.77 | 29,626,485.56 | 16,618,529.90 | 57,796,443.95 | 30,945,246.47 |
| 自主研发技术成果转化(元) | 248,802,477.52 | 392,419,534.29 | 190,124,937.82 | 220,879,747.98 | 69,169,611.13 |
| 临床服务(元) | 92,585,687.43 | 192,878,146.07 | 70,022,084.10 | 79,948,250.32 | 43,426,628.26 |
| 商业化生产(元) | 2,518,324.69 | - | - | - | - |
| 其他(元) | 17,157,152.95 | 11,920,431.18 | 5,160,217.66 | 9,581,253.08 | 4,438,980.44 |
| 营业成本(元) | |||||
| CDMO收入(元) | 2,231,238.69 | - | 9,746,493.39 | 14,132,313.56 | 4,802,625.77 |
| 临床前药学研究(元) | 48,417,655.20 | 119,159,501.34 | 52,099,624.64 | 86,273,148.01 | 37,372,144.27 |
| 权益分成(元) | - | - | - | - | 209,798.49 |
| 自主研发技术成果转化(元) | 36,292,616.44 | 83,891,082.43 | 32,747,458.39 | 48,562,515.44 | 16,695,175.99 |
| 临床服务(元) | 57,979,307.95 | 107,976,710.03 | 42,556,762.96 | 43,690,283.51 | 23,199,675.23 |
| 商业化生产(元) | 5,853,041.07 | - | - | - | - |
| 其他(元) | 13,295,636.02 | 9,335,257.76 | 4,593,097.69 | 5,521,591.72 | 2,264,620.57 |
| 毛利(元) | |||||
| CDMO收入(元) | 2,889,262.73 | - | 7,529,230.31 | 6,669,848.65 | 2,540,506.88 |
| 临床前药学研究(元) | 105,905,591.14 | 218,950,595.29 | 72,560,966.41 | 132,129,533.61 | 52,972,406.70 |
| 权益分成(元) | 4,554,144.77 | - | 16,618,529.90 | 57,796,443.95 | 30,735,447.98 |
| 自主研发技术成果转化(元) | 212,509,861.08 | 308,528,451.86 | 157,377,479.43 | 172,317,232.54 | 52,474,435.14 |
| 临床服务(元) | 34,606,379.48 | 84,901,436.04 | 27,465,321.14 | 36,257,966.81 | 20,226,953.03 |
| 商业化生产(元) | -3,334,716.38 | - | - | - | - |
| 其他(元) | 3,861,516.93 | 2,585,173.42 | 567,119.97 | 4,059,661.36 | 2,174,359.87 |
| 毛利率(%) | |||||
| CDMO收入(%) | 56.43 | - | 43.58 | 32.06 | 34.60 |
| 临床前药学研究(%) | 68.63 | 64.76 | 58.21 | 60.50 | 58.63 |
| 权益分成(%) | - | - | - | - | 99.32 |
| 自主研发技术成果转化(%) | 85.41 | 78.62 | 82.78 | 78.01 | 75.86 |
| 临床服务(%) | 37.38 | 44.02 | 39.22 | 45.35 | 46.58 |
| 商业化生产(%) | -132.42 | - | - | - | - |
| 其他(%) | 22.51 | 21.69 | 10.99 | 42.37 | 48.98 |
| 收入构成(%) | |||||
| CDMO收入(%) | 0.98 | 5.16 | 4.08 | 3.42 | 2.99 |
| 临床前药学研究(%) | 29.39 | 33.23 | 29.41 | 35.96 | 36.78 |
| 权益分成(%) | 0.87 | 2.91 | 3.92 | 9.52 | 12.60 |
| 自主研发技术成果转化(%) | 47.39 | 38.57 | 44.86 | 36.36 | 28.16 |
| 临床服务(%) | 17.63 | 18.96 | 16.52 | 13.16 | 17.68 |
| 商业化生产(%) | 0.48 | - | - | - | - |
| 其他(%) | 3.27 | 1.17 | 1.22 | 1.58 | 1.81 |
| 毛利构成(%) | |||||
| CDMO收入(%) | 0.80 | 0.00 | 2.67 | 1.63 | 1.58 |
| 临床前药学研究(%) | 29.34 | 35.60 | 25.72 | 32.29 | 32.88 |
| 权益分成(%) | 1.26 | 0.00 | 5.89 | 14.12 | 19.08 |
| 自主研发技术成果转化(%) | 58.87 | 50.17 | 55.78 | 42.11 | 32.57 |
| 临床服务(%) | 9.59 | 13.81 | 9.74 | 8.86 | 12.55 |
| 商业化生产(%) | -0.92 | - | - | - | - |
| 其他(%) | 1.07 | 0.42 | 0.20 | 0.99 | 1.35 |